首页> 外文学位 >Cyclooxygenase-2 renoprotective effects during chronically augmented and attenuated endogenous AngII activity.
【24h】

Cyclooxygenase-2 renoprotective effects during chronically augmented and attenuated endogenous AngII activity.

机译:在慢性增强和减弱内源性AngII活性期间,环氧合酶2的肾脏保护作用。

获取原文
获取原文并翻译 | 示例

摘要

Cyclooxygenase (COX) isoforms, COX1 and COX2, generate renal prostaglandin E2, prostaglandin I2 and thromboxane A2. Nonselective COX inhibitors decrease prostaglandin vasodilatory influence on total renal and vasa recta blood flow, especially in resistance vessels preconstricted with angiotensin II (AngII). While this signifies prostaglandin regulation of renal blood flow, each COX isoform's regulatory contribution remains unresolved. The significance of each enzyme can potentially be discriminated during conditions that selective regulate isoform expression. Angiotensin converting enzyme (ACE) inhibition selectively increases cortical COX2 and dietary salt restriction differentially increases cortical COX2 while decreasing cortical COX-1.;Interestingly, sodium-restricted animals show normal or only slightly lowered renal hemodynamic parameters despite high plasma renin activity. It remains unresolved whether the concurrently augmented COX-2 expression in sodium restricted animals yield vasodilatory influence to maintain renal hemodynamic parameters by opposing or modifying AngII effects. Hence, we tested the hypothesis that COX-2 inhibitor effects on renal hemodynamic and excretory function are increased in proportion to AngII activity.;Renal clearance experiments were conducted in four groups of anesthetized Sprague-Dawley rats: those characterized by attenuated AngII activity established by acute captopril either (1) alone (aACEi) or (2) in combination with chronic captopril pretreatment (cACEi); in contrast to rats fed (3) normal (NS) or (4) low (LS) sodium diet, respectively. Acute COX-2 inhibition with nimesulide (NMSLD) was thereafter used to investigate the activity of basal or augmented cortical COX-2 expression. NMSLD did not alter mean arterial blood pressure in any group but decreased renal plasma flow(RPF), cortical blood flow (CBF) and glomerular filtration rate (GFR) in the LS and cACEi groups. In contrast, medullary blood flow (MBF) was significantly decreased by COX-2 inhibition in all groups. Absolute (UNalpha) and fractional (FENalpha) sodium excretion rates were unchanged by NMSLD except in the LS group. These results demonstrate an augmented COX-2-mediated vasodilatation that is AngII-independent in contrast to an augmented COX-2-mediated sodium excretion where AngII activity is requisite. Further, COX-2 effects on MBF are neither AngII-dependent nor dependent on changes in cortical microvascular responses. Therefore, COX-2 continually regulates MBF and responsively limits AngII prohypertensinogenic effects on RPF, CBF, GFR, UNalpha and FENalpha.
机译:环氧合酶(COX)异构体COX1和COX2产生肾脏前列腺素E2,前列腺素I2和血栓烷A2。非选择性COX抑制剂可减少前列腺素对总肾脏和血管直肠血流量的血管舒张作用,特别是在血管紧张素II(AngII)预先收缩的抵抗血管中。尽管这表示前列腺素对肾血流的调节,但每种COX亚型的调节作用仍未解决。在选择性调节亚型表达的条件下,可能会区分每种酶的重要性。血管紧张素转化酶(ACE)抑制选择性地增加了皮质COX2,而饮食盐限制则不同地增加了皮质COX2,同时降低了皮质COX-1。有趣的是,尽管血浆肾素活性很高,但钠限制的动物显示出正常或仅略微降低的肾脏血液动力学参数。钠受限动物中同时增加的COX-2表达是否产生血管舒张作用以通过对抗或改变AngII效应维持肾脏血液动力学参数仍未解决。因此,我们检验了以下假设:COX-2抑制剂对肾血流动力学和排泄功能的影响与AngII活性成比例增加。肾脏清除实验在四组麻醉的Sprague-Dawley大鼠中进行:以AngII活性减弱为特征的大鼠急性卡托普利(1)单独(aACEi)或(2)联合慢性卡托普利预处理(cACEi);与分别饲喂(3)正常(NS)或(4)低(LS)钠饮食的大鼠相反。尼美舒利(NMSLD)的急性COX-2抑制作用随后用于研究基底或皮质COX-2表达增强的活性。 NMSLD并没有改变任何一组的平均动脉血压,但是在LS和cACEi组中肾血浆流量(RPF),皮质血液流量(CBF)和肾小球滤过率(GFR)降低了。相反,在所有组中,通过COX-2抑制,髓样血流量(MBF)均显着降低。除LS组外,NMSLD的钠排泄率(UNalpha)和分数排泄率(FENalpha)均无变化。这些结果表明,与AngII活性是必需的COX-2介导的钠排泄增强相比,COX-2介导的血管舒张是独立于AngII的。此外,COX-2对MBF的作用既不依赖于AngII,也不依赖于皮层微血管反应的变化。因此,COX-2持续调节MBF并响应性地限制AngII对RPF,CBF,GFR,UNalpha和FENalpha的降压作用。

著录项

  • 作者

    Green, Torrance.;

  • 作者单位

    Tulane University.;

  • 授予单位 Tulane University.;
  • 学科 Biology Physiology.
  • 学位 Ph.D.
  • 年度 2010
  • 页码 157 p.
  • 总页数 157
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号